Global Lung Cancer Therapeutics Market, By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumours, Mediastinal Tumours, Mesothelioma, Chest Wall Tumours), Molecule Type (Small Molecules and Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors and Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy and Others), Therapy Type (Single Drug Therapy and Combination Therapy), End User (Hospitals, Homecare, Speciality Clinics and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online and Others) – Industry Trends and Forecast to 2029
Global Lung Cancer Therapeutics Market Analysis and Size
Cancer refers to a disease of genes that are caused due to abnormal growth of cells. Through blood and lymph system these abnormal cells further migrate from the original site to other site. Lung cancer is type of cancer that is formed in tissues of the lungs. The rise in awareness regarding cancer is escalating the growth of lung cancer therapeutics market.
- Small cell lung cancer, lung carcinoid tumor and non-small cell lung cancer are three different types of lung cancer. Global lung cancer therapeutics market was valued at USD 24,667.82 million in 2021 and is expected to reach USD 54,475.11 million by 2029, registering a CAGR of 10.41% during the forecast period of 2022-2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Global Lung Cancer Therapeutics Market Definition
Lung Cancer therapeutic refer to the therapies that include drugs and surgery aimed to stunt, kill, diminish or destroy the cancerous growth and cells in the lungs. This type of cancer is treated through chemotherapy, immunotherapy, surgery, and radiation therapy. The primary lung carcinomas usually originate from the epithelial cells.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumours, Mediastinal Tumours, Mesothelioma, Chest Wall Tumours), Molecule Type (Small Molecules and Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors and Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy and Others), Therapy Type (Single Drug Therapy and Combination Therapy), End User (Hospitals, Homecare, Speciality Clinics and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Church & Dwight Co., Inc. (US), GlaxoSmithKline plc. (UK), Pfizer Inc. (US), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Limited (Japan), ONO PHARMACEUTICAL CO., LTD. (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Lily. (US), AstraZeneca (US), Boehringer Ingelheim International GmbH (Germany), Merck & Co., Inc. (US), CELGENE CORPORATION (US), Sanofi (France), Johnson & Johnson Services, Inc. (US), Dr. Reddy’s Laboratories Ltd. (India), ALLERGAN (Ireland), Teva Pharmaceutical Industries Ltd. (Israel), and Bristol-Myers Squibb Company (US), among others
|
Lung Cancer Therapeutics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:
- Prevalence of Unhealthy Lifestyles
The rise in the adoption of the unhealthy lifestyles, such as smoking acts as one of the major factors driving the growth of lung cancer therapeutics market. Cigarette smoking is known to be prominent cause of lung cancer.
- Demand for Targeted Therapies
The increase in the demand for targeted therapies, including chemotherapy, immunotherapy, surgery, and radiation therapy to treat lung cancer accelerate the market growth.
- Presence of Highly Efficient Drugs
The presence of highly efficient drugs, such as avastin, gemzar, taxotere and tarceva further influence the market.
Opportunities
Furthermore, arrival of nanomedicine to treat lung cancer extend profitable opportunities to the market players in the forecast period of 2022 to 2029. Also, growing approvals in the lung cancer therapeutics will further expand the market.
Restraints/Challenges Global Lung Cancer Therapeutics Market
On the other hand, presence of poor cancer diagnostic facilities in many countries and the adverse effects of chemotherapies are expected to obstruct market growth. Also, stringent regulations are projected to challenge the lung cancer therapeutics market in the forecast period of 2022-2029.
This lung cancer therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on lung cancer therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Lung Cancer Therapeutics Market
The medical services such as lung cancer therapeutics witnessed decline in revenues in the years 2020 and 2021 due to the outbreak of COVID-19. Major medical procedures were declined during the pandemic in order to prevent the risk of spreading coronavirus. However, rise in the lung cancer therapeutics procedures is expected in the post-COVID owing to the easing of restrictions.
Recent Development
- AdoRx Therapeutics, announced regarding their strategic collaboration with Lung Cancer Initiative at Johnson & Johnson and Johnson & Johnson Innovation LLC in February’2019. AdoRx has granted an exclusive option to research, develop and commercialise novel antagonists under the terms of the agreement.
Global Lung Cancer Therapeutics Market Scope and Market Size
The biomarkers market is segmented on the basis of cancer type, molecule type, drug class, treatment type, therapy type, end user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Cancer Type
- Non-Small Cell Lung Cancer
- Metastatic Lung Cancer
- Mesothelioma
- Chest Wall Tumours
- Pulmonary Neuroendocrine Tumours
- Mediastinal Tumours
On the basis of cancer type, the lung cancer therapeutics market is segmented into non-small cell lung cancer, metastatic lung cancer, mesothelioma, chest wall tumours, pulmonary neuroendocrine tumours and mediastinal tumours.
Molecule Type
- Small Molecules
- Biologics
On the basis of molecule type, the lung cancer therapeutics market is segmented into small molecules and biologics.
Drug Class
- Alkylating Agents
- Antimetabolites
- Mitotic Inhibitors
- Multikinase Inhibitors
- EGFR Inhibitors
- Others
On the drug class, the lung cancer therapeutics market is segmented into alkylating agents, antimetabolites, mitotic inhibitors, multikinase inhibitors, EGFR inhibitors and others.
Treatment Type
- Radiation Therapy
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Other Drugs
On the basis of treatment type, the lung cancer therapeutics market is segmented into radiation therapy, chemotherapy, targeted therapy, immunotherapy, and other drugs.
Therapy Type
- Single Drug Therapy
- Combination Therapy
On the basis of therapy type, the lung cancer therapeutics market is segmented into single drug therapy and combination therapy.
End User
- Hospitals
- Specialty Clinics
- Homecare
- Others
On the basis of end user, the lung cancer therapeutics market is segmented into hospitals, specialty clinics, homecare and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online
- Others
On the basis of distribution channel, the lung cancer therapeutics market is segmented into hospital pharmacy, retail pharmacy, online and others.
Lung Cancer Therapeutics Market Regional Analysis/Insights
The lung cancer therapeutics market is analysed and market size insights and trends are provided by country, cancer type, molecule type, drug class, treatment type, therapy type, end user and distribution channel as referenced above.
The countries covered in the lung cancer therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the lung cancer therapeutics market because of the rise in incidence of lung cancer and growing aging population within the region.
Asia-Pacific (APAC) is expected to witness significant growth during the forecast period of 2022 to 2029 due to the increased use of lung cancer therapeutic due to rising tobacco smoking in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The lung cancer therapeutics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for lung cancer therapeutics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the lung cancer therapeutics market. The data is available for historic period 2010-2020.
Competitive Landscape and Lung Cancer Therapeutics Market Share Analysis
The lung cancer therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to lung cancer therapeutics market.
Some of the major players operating in the lung cancer therapeutics market are Church & Dwight Co., Inc. (US), GlaxoSmithKline plc. (UK), Pfizer Inc. (US), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Limited (Japan), ONO PHARMACEUTICAL CO., LTD. (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Lily. (US), AstraZeneca (US), Boehringer Ingelheim International GmbH (Germany), Merck & Co., Inc. (US), CELGENE CORPORATION (US), Sanofi (France), Johnson & Johnson Services, Inc. (US), Dr. Reddy’s Laboratories Ltd. (India), ALLERGAN (Ireland), Teva Pharmaceutical Industries Ltd. (Israel), and Bristol-Myers Squibb Company (US), among others.
Research Methodology : Global Lung Cancer Therapeutics Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-lung-cancer-therapeutics-market
Customization Available : Global Lung Cancer Therapeutics Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.
SKU-